Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Erythromycin

FDA-approved product (ointment, ophthalmic), marketed as A/T/S, Akne-Mycin, C-Solve-2 and 34 more.

Registered studies
50+
Lab records
32
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Erythromycin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Acne
  • Bacterial disease
  • Eye infection
  • Infection
  • Whooping cough

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Antiinfectives for treatment of acne; Macrolides; Antibiotics
FDA pharmacologic class
Macrolide; Macrolide Antimicrobial FDA label ↗
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC D10AF02; WHO ATC D10AF52; WHO ATC J01FA01; WHO ATC S01AA17

Repurposing investigation

Erythromycin is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA28.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli3.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae52.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis71.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • MRSA: measured active in 17 of 25 lab records
  • E. coli: measured active in 0 of 1 lab record
  • K. pneumoniae: measured active in 6 of 6 lab records
Open Erythromycin in ChEMBL Registered studies below
Show the 32 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Erythromycin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Collagen Peptides and Cellular Aging

    NCT07456449 · start 2026-04-22

    Registered record
    Registry ID
    NCT07456449
    Conditions
    Longevity; Healthy Aging; Biological Ageing
    Interventions
    Collagen peptides; Maltodextrin (Placebo)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2026-04-22
    Completion
    2028-08
    Enrolment
    125

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLongevity; Healthy Aging; Biological Ageing
    InterventionCollagen peptides; Maltodextrin (Placebo)
    PhaseNot applicable
    Registry statusRecruiting

  • Individualizing Treatment for Asthma in Primary Care (Full Study)

    NCT07052942 · start 2025-08-01

    Registered record
    Registry ID
    NCT07052942
    Conditions
    Asthma; Asthma Attack; Asthma Exacerbations
    Interventions
    Inhaled corticosteroid (ICS); Azithromycin; Asthma Symptom Monitoring Web-based Application
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2025-08-01
    Completion
    2029-11-15
    Enrolment
    3,200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAsthma; Asthma Attack; Asthma Exacerbations
    InterventionInhaled corticosteroid (ICS); Azithromycin; Asthma Symptom Monitoring Web-based Application
    PhasePhase 4
    Registry statusRecruiting

  • Drug-Drug Interactions Between TNP-2198 and Midazolam, Clarithromycin

    NCT06551623 · start 2024-08-26

    Registered record
    Registry ID
    NCT06551623
    Conditions
    Helicobacter Pylori Infection
    Interventions
    Midazolam; Clarithromycin; TNP-2198
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2024-08-26
    Completion
    2024-10-14
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Infection
    InterventionMidazolam; Clarithromycin; TNP-2198
    PhasePhase 1
    Registry statusCompleted

  • Effect of Pharmacokinetics in Healthy Chinese Subjects

    NCT06005714 · start 2023-08-15

    Registered record
    Registry ID
    NCT06005714
    Conditions
    The Effects of Clarithromycin or Cyclosporine on Pharmacokinetics of Deuterium Hydrobromide Ramidvir Tablets in Healthy Chinese Subjects
    Interventions
    Mindeudesivir hydrobromide tablets and Clarithromycin tablets; Mindeudesivir hydrobromide tablets and Cyclosporine softgels
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2023-08-15
    Completion
    2023-10-31
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionThe Effects of Clarithromycin or Cyclosporine on Pharmacokinetics of Deuterium Hydrobromide Ramidvir Tablets in Healthy Chinese Subjects
    InterventionMindeudesivir hydrobromide tablets and Clarithromycin tablets; Mindeudesivir hydrobromide tablets and Cyclosporine softgels
    PhasePhase 1
    Registry statusCompleted

  • Azithromycin Before Induction

    NCT06543290 · start 2023-08-07

    Registered record
    Registry ID
    NCT06543290
    Conditions
    Infections
    Interventions
    Azithromycin Pill; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2023-08-07
    Completion
    2026-08-07
    Enrolment
    400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfections
    InterventionAzithromycin Pill; Placebo
    PhasePhase 1
    Registry statusRecruiting

  • Azithromycin for Severe Acute Malnutrition in CMAM, Nigeria

    NCT05473234 · start 2022-10-06

    Registered record
    Registry ID
    NCT05473234
    Conditions
    Severe Acute Malnutrition
    Interventions
    Azithromycin; Amoxicillin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2022-10-06
    Completion
    2023-11-29
    Enrolment
    310

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSevere Acute Malnutrition
    InterventionAzithromycin; Amoxicillin
    PhasePhase 3
    Registry statusTerminated

  • A "Screen and Treat" Helicobacter Pylori Eradication Trial in Adolescents in Three Regions of Chile

    NCT05926804 · start 2022-08-02

    Registered record
    Registry ID
    NCT05926804
    Conditions
    Helicobacter Pylori Infection
    Interventions
    Lansoprazole; Amoxicillin; Clarithromycin; Metronidazole
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2022-08-02
    Completion
    2027-08
    Enrolment
    500

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Infection
    InterventionLansoprazole; Amoxicillin; Clarithromycin; Metronidazole
    PhaseNot applicable
    Registry statusRecruiting

  • Helicobacter Pylori Eradication and Follow-up

    NCT05061732 · start 2021-09-30

    Registered record
    Registry ID
    NCT05061732
    Conditions
    Helicobacter Pylori Infection
    Interventions
    Rabeprazole; Bismuth potassium citrate; Metronidazole; Clarithromycin; Levofloxacin; Amoxicillin; Metronidazole; Doxycycline; Tetracycline
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2021-09-30
    Completion
    2026-06-30
    Enrolment
    4,447

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Infection
    InterventionRabeprazole; Bismuth potassium citrate; Metronidazole; Clarithromycin +5 more
    PhasePhase 4
    Registry statusUnknown

  • Susceptibility Testing of Biofilm to Guide Treatment of Periprosthetic Joint Infections

    NCT04488458 · start 2021-08-15

    Registered record
    Registry ID
    NCT04488458
    Conditions
    Prosthetic Joint Infection; Prosthetic Infection; Hip Prosthesis Infection; Knee Prosthesis Infection
    Interventions
    MIC or MBEC+MIC based treatment algorithm
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2021-08-15
    Completion
    2023-12-31
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProsthetic Joint Infection; Prosthetic Infection; Hip Prosthesis Infection; Knee Prosthesis Infection
    InterventionMIC or MBEC+MIC based treatment algorithm
    PhaseNot applicable
    Registry statusUnknown

  • Recurrence Rate Comparison Between Esomeprazole and Lansoprazole in Eradicating Helicobacter Pylori Infection Among Children

    NCT05861687 · start 2021-08-01

    Registered record
    Registry ID
    NCT05861687
    Conditions
    Helicobacter Pylori Infection
    Interventions
    Esomeprazole; Lansoprazole; Amoxicillin; Clarithromycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2021-08-01
    Completion
    2022-05-20
    Enrolment
    51

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Infection
    InterventionEsomeprazole; Lansoprazole; Amoxicillin; Clarithromycin
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Resiliency Through Azithromycin for Children (REACH), Côte d'Ivoire

    NCT04617626 · start 2020-11-20

    Registered record
    Registry ID
    NCT04617626
    Conditions
    Child Mortality; Azithromycin
    Interventions
    Azithromycin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2020-11-20
    Completion
    2021-01-31
    Enrolment
    1,735

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChild Mortality; Azithromycin
    InterventionAzithromycin
    PhaseNot applicable
    Registry statusCompleted

  • Drug-drug Interactions and Safety Among JP-1366, Amoxicillin, and Clarithromycin in Healthy Volunteers

    NCT05194046 · start 2020-11-18

    Registered record
    Registry ID
    NCT05194046
    Conditions
    Helicobacter Pylori Associated Gastrointestinal Disease
    Interventions
    JP-1366 20mg 1capsule; Amoxicillin 500Mg Cap; Clarithromycin 500Mg Tab
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2020-11-18
    Completion
    2021-01-19
    Enrolment
    29

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Associated Gastrointestinal Disease
    InterventionJP-1366 20mg 1capsule; Amoxicillin 500Mg Cap; Clarithromycin 500Mg Tab
    PhasePhase 1
    Registry statusCompleted

  • Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Participants With B-Cell Malignancies

    NCT04551963 · start 2020-11-15

    Registered record
    Registry ID
    NCT04551963
    Conditions
    B-cell Malignancies
    Interventions
    Zanubrutinib; Fluconazole; Diltiazem; Voriconazole; Clarithromycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2020-11-15
    Completion
    2022-02-21
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionB-cell Malignancies
    InterventionZanubrutinib; Fluconazole; Diltiazem; Voriconazole +1 more
    PhasePhase 1
    Registry statusCompleted

  • Azithromycin Treatment for Readthrough of APC Gene Stop Codon Mutations in Familial Adenomatous Polyposis

    NCT04454151 · start 2020-08-01

    Registered record
    Registry ID
    NCT04454151
    Conditions
    Familial Adenomatous Polyposis
    Interventions
    Azithromycin Tablets
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2020-08-01
    Completion
    2022-04-01
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFamilial Adenomatous Polyposis
    InterventionAzithromycin Tablets
    PhasePhase 4
    Registry statusUnknown

  • Efficacy of Azithromycin-associated Hydroxychloroquine Therapy Given in General Practice in Early-stage Disease in COVID-19 Patients

    NCT04371406 · start 2020-04

    Registered record
    Registry ID
    NCT04371406
    Conditions
    Covid-19
    Interventions
    Hydroxychloroquine and Azithromycin; Azinc
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2020-04
    Completion
    2020-09
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCovid-19
    InterventionHydroxychloroquine and Azithromycin; Azinc
    PhasePhase 3
    Registry statusWithdrawn